GlassScriptPhysician profile
Amita Bagal
NPI 1114997301
$2,721.17
in general payments reported to CMS, 2019-2025
28 companies · $665 in 2025
The $665 reported for 2025 was more than what 77% of Plastic Surgery Within The Head and Neck providers received nationally (typical 2025 total: $300).
See the full distribution for Plastic Surgery Within the Head and Neck
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $106 · 2021: $375 · 2022: $386 · 2023: $681 · 2024: $306 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.37 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $181.51 | 2019-2025 | Libtayo |
| Leo Pharma INC. | $166.87 | 2022-2024 | Adbry |
| Janssen Biotech, INC. | $147.49 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $141.13 | 2019-2025 | Nemluvio, Aklief |
| Incyte Corporation | $133.44 | 2023-2025 | Opzelura |
| Ucb, INC. | $100.65 | 2019-2025 | Bimzelx |
| Organon LLC | $81.16 | 2025 | |
| Sun Pharmaceutical Industries INC. | $63.56 | 2022-2024 | |
| Pfizer INC. | $58.81 | 2023-2025 | |
| Boston Scientific Corporation | $58.61 | 2023-2025 | Varithena Administration Pack |
| Organogenesis INC. | $56.46 | 2025 | Puraply Wound Matrix, Via Matrix |
| Hill Dermaceuticals, INC. | $51.33 | 2021 | |
| Biowound Solutions, INC. | $29.54 | 2025 | Bio-Connekt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.84 | 2025 | Spevigo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $21.95 | 2023 | |
| Mimedx Group, INC. | $21.87 | 2024 | |
| Musculoskeletal Transplant Foundation INC. | $20.63 | 2023 | |
| Kyowa Kirin, INC. | $20.60 | 2022 | |
| Vyne Pharmaceuticals INC. | $19.83 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.83 | 2025 | Sotyktu |
| Lilly USA, LLC | $17.89 | 2021 | |
| Genentech USA, INC. | $17.88 | 2021 | |
| Celgene Corporation | $17.30 | 2019 | |
| Almirall LLC | $15.74 | 2019 | |
| Biofrontera INC. | $15.50 | 2020 | |
| Arcutis Biotherapeutics, INC. | $14.35 | 2025 | Zoryve |
| Mission Pharmacal Company | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amita Bagal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.